Search details
1.
Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms.
Blood
; 141(8): 917-929, 2023 02 23.
Article
in English
| MEDLINE | ID: mdl-36356299
2.
Impact of non-driver gene mutations on thrombo-haemorrhagic events in ET patients.
Br J Haematol
; 204(1): 221-228, 2024 01.
Article
in English
| MEDLINE | ID: mdl-37920129
3.
Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia.
Eur J Haematol
; 110(2): 131-136, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36208190
4.
Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia.
J Thromb Thrombolysis
; 55(2): 263-272, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36484956
5.
CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms.
Cancer Sci
; 112(2): 884-892, 2021 Feb.
Article
in English
| MEDLINE | ID: mdl-33280191
6.
Increased SLAMF7high monocytes in myelofibrosis patients harboring JAK2V617F provide a therapeutic target of elotuzumab.
Blood
; 134(10): 814-825, 2019 09 05.
Article
in English
| MEDLINE | ID: mdl-31270105
7.
Mechanism underlying the development of myeloproliferative neoplasms through mutant calreticulin.
Cancer Sci
; 111(8): 2682-2688, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32462673
8.
[Mutant calreticulin and the molecular mechanisms in development of myeloproliferative neoplasms].
Rinsho Ketsueki
; 61(8): 937-944, 2020.
Article
in Japanese
| MEDLINE | ID: mdl-32908058
9.
Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
Eur J Haematol
; 102(6): 516-520, 2019 Jun.
Article
in English
| MEDLINE | ID: mdl-30977935
10.
Histone Acetyltransferase p300/CREB-binding Protein-associated Factor (PCAF) Is Required for All-trans-retinoic Acid-induced Granulocytic Differentiation in Leukemia Cells.
J Biol Chem
; 292(7): 2815-2829, 2017 02 17.
Article
in English
| MEDLINE | ID: mdl-28053092
11.
Skewed megakaryopoiesis in human induced pluripotent stem cell-derived haematopoietic progenitor cells harbouring calreticulin mutations.
Br J Haematol
; 181(6): 791-802, 2018 06.
Article
in English
| MEDLINE | ID: mdl-29741776
12.
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Blood
; 127(10): 1307-16, 2016 Mar 10.
Article
in English
| MEDLINE | ID: mdl-26817954
13.
The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.
Eur J Haematol
; 100(6): 544-549, 2018 Jun.
Article
in English
| MEDLINE | ID: mdl-29405428
14.
[Development of myeloproliferative neoplasms by mutant calreticulin: underlying mechanisms].
Rinsho Ketsueki
; 59(8): 1072-1077, 2018.
Article
in Japanese
| MEDLINE | ID: mdl-30185708
15.
Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.
Cancer Sci
; 108(10): 1907-1912, 2017 Oct.
Article
in English
| MEDLINE | ID: mdl-28741795
16.
Gene mutations in myeloproliferative neoplasms.
Rinsho Ketsueki
; 57(12): 2526-2534, 2016.
Article
in Japanese
| MEDLINE | ID: mdl-28090022
17.
Platelet-derived growth factor receptors form complexes with neuropilin-1 during megakaryocytic differentiation of thrombopoietin-dependent UT-7/TPO cells.
Biochem Biophys Res Commun
; 459(3): 443-9, 2015 Apr 10.
Article
in English
| MEDLINE | ID: mdl-25744030
18.
[Current problems in the diagnosis of Philadelphia-negative myeloproliferative neoplasms in Japan].
Rinsho Ketsueki
; 56(7): 877-82, 2015 Jul.
Article
in Japanese
| MEDLINE | ID: mdl-26251152
19.
JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
Br J Haematol
; 187(1): e27-e31, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31418453
20.
Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy.
Haematologica
; 104(11): e506-e509, 2019 11.
Article
in English
| MEDLINE | ID: mdl-30948490